Men with type-1 diabetes might be able to grow new insulin cells from their own testicular tissue, according to a new study. Testicular treatment could even be safer and more effective than stem-cell therapies.
Using stem cell technology, scientists have produced male and female mice from two fathers, a breakthrough that could conceivably allow same-sex couples to have their own genetic children.
The multi-generational technique combines genes from the chromosomes of two male mice and uses surrogate mothers, according to researchers at the M.D. Anderson Cancer Center at the University of Texas.
And to think we once thought spray-on bandages were revolutionary. Doctors at the University of Utah’s Burn Care Center are reporting success in their pilot project testing stem cell solutions sprayed directly onto burns.
Canadian researchers have turned skin cells into blood cells, a breakthrough that could lead to new cancer therapies while avoiding the controversial use of stem cells.
With the new technique, people who need blood for surgery, cancer treatment or other conditions could have a ready supply of their own blood, made from a patch of skin.
By Lana BirbrairPosted 10.26.2010 at 5:00 pm 13 Comments
Like a child, a stem cell can grow up to be just about anything. Eventually it picks a job, however, during a process called differentiation. Scientists can influence, if not always control, the outcome by applying compounds called growth factors. Now Jianping Fu, a biomedical and mechanical engineer at the University of Michigan, and his colleagues have discovered that the force exerted by a stem cell onto a surface is an important part of in both predicting and altering what type of cell it will develop into.
The objections surrounding the use of embryonic stem cells in organ and tissue reconstruction could be silenced if clinical trials for a new strain of stem cells derived from liposuctioned fat get a nod of approval from the FDA. And if they do, their first order of business will probably be growing bigger breasts.
The push-pull between the Obama administration and U.S. District Judge Royce Lamberth over the government's funding of embryonic stem cell research has swung back the other way, at least temporarily lifting the temporary injunction blocking federal funding for embryonic stem cell research that was issued last month.
Researchers at dozens of labs across the country are scrambling today to figure out exactly where their research stands and if feeding their cell cultures is even legal after a ruling handed down yesterday by a federal judge blocked President Obama's 2009 executive order expanding the scope of embryonic stem cell research. At issue: Whether or not Obama's policy violates a federal ban on federal money contributing to the destruction of embryos. At stake: A whole lot of ongoing medical science that could be cut down in stride.
Human pluripotent stem cells – the kind that can become any kind of specialized cell and therefore be used to treat pretty much any kind of cellular damage – hold seemingly limitless promise if only we could manipulate them in useful quantities. Now, researchers at MIT have overcome a major obstacle to both stem cell study and eventual stem cell treatments by creating a synthetic surface that enables stem cells to live and multiply for months, producing clinically-useful quantities of identical cells.
Last week, the FDA gave biotech firm Geron the green light to proceed with clinical trials of an embryonic stem cell treatment for spinal cord injuries. But while we wait on promising embryonic stem cell research to clear political and regulatory hurdles, adult stem cell research is trucking right along. Yesterday it was announced that Iraq War veteran and Marine Matt Cole, paralyzed from the chest down since a 2005 insurgent attack in Iraq, has enrolled as the first patient in the first FDA clinical trial of adult stem cells used to treat spinal cord injuries.